Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576328 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
A Phase 1 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01576328 is a Phase 1 study that has completed, run by Mesoblast. The registered enrollment target is 61 participants.
The verdict
NCT01576328, a Phase 1 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on Metformin.
Interventions
- DRUG Mesenchymal Precursor Cells (MPCs)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01576328
The ClinicalTrials.gov registry entry for NCT01576328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mesenchymal Precursor Cells (MPCs) is the first listed.
NCT01576328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01576328 about?
NCT01576328 is a clinical study titled "Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes". This study is being conducted to assess the overall safety and tolerability of a single intravenous infusion of three doses of Mesenchymal Precursor Cells versus Placebo in subjects with Type 2 Diabetes inadequately controlled on Metformin.
What is the current status of trial NCT01576328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2012-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01576328?
The interventions under investigation include: Mesenchymal Precursor Cells (MPCs) (DRUG).
Who is sponsoring clinical trial NCT01576328?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.